Search 

Using unexploited novel machine learning methods, Etcembly has developed a proprietary machine learning platform (EMLy) that interprets T-cell receptor (TCR) repertoires for the effective design of personalized therapeutics for cancer treatment. Etcembly partners with biotechnology companies to identify the ideal TCR for immunotherapies, and will become the partner of choice in TCR therapy design and optimization.

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company’s lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core area, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen’s Sulforadex® technology.

The Company has its headquarters and registered office at Alderley Park, Cheshire.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

Established in 2001, Fusion Antibodies is a Collaborative Research Organisation (CRO) with its headquarters in Northern Ireland. We are world leaders in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics to clinical Cell Line Development.

We have guided hundreds of projects through critical pre-clinical stages, repeatedly proving our expertise as we strive to bring about a positive change in the healthcare industry.

Our approach to engineering and optimization is often to harness the power of the natural somatic hypermutation space. Fusion offers flexibility and agility while delivering clinical candidates focusing on developability, manufacturability and function.

Fusion has developed a number of unique, proprietary technology platforms. Our suite of development capabilities include:
·       Antibody humanization (CDRx™)

·       Affinity maturation (RAMP™)

·       Protein engineering

·       Discovery (mouse hybridoma and rabbit B cell approaches)

·       Protein production – CHO and other mammalian systems

·       Cell Line Development – cGMP ready mammalian cell lines (up to 8 g/L)

·       Expert scientific & technical advisory services

·       Bespoke & collaborative large-scale research and development programs